RxDoctor Payments Data

Jose Perez Becerra, MD

Ophthalmology · San Antonio, TXNPI 1114943941

Payments from drug & device makers

$843in general payments, 2019–2025

Across 20 payments — averaging $42.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$249
  • Alcon$144
  • Biotissue Holdings Inc.$128
  • Johnson & Johnson Surgical Vision, Inc.$117
  • Ocular Therapeutix, Inc.$107
  • Oyster Point Pharma, Inc.$36
  • plus $62 from 3 others

What the payments were for

  • Food & beverage$843100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$843 in reported general payments places this provider in the 30th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$106,659
Medicare patients
486
Services billed
1,356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost101$65,087
RestasisCyclosporine33$31,331
XiidraLifitegrast17$23,438
Alphagan PBrimonidine Tartrate16$8,091
Latanoprost673$7,720
CombiganBrimonidine Tartrate/Timolol15$6,487
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$2,674
Travoprost15$2,460
Brimonidine Tartrate55$2,113
Prednisolone Acetate47$1,864
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat91$1,005
Timolol Maleate43$586
Doxycycline Hyclate20$526
Dorzolamide Hcl29$372
ErythromycinErythromycin Base25$269

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$249$110,996165 claims
Bausch & Lomb Americas Inc.Xiidra$20$23,43817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →